Sunitinib enhances marrow and peripheral myeloid engraftment after BMT into Rag1−/− recipients. CD45.2+Rag1−/− recipients received daily doses of sunitinib or vehicle on days −3 through 0, then 5 × 106 TCD BM cells from WT CD45.1+C57Bl/6 mice on days 0 and 1. (A) Representative flow cytometry plots of gated Lin− marrow on day 28 show increased donor-derived progenitors in sunitinib recipients. (B-C) Mean donor-derived marrow Lin− cell frequencies and splenic myeloid cells from groups of Rag1−/− recipients treated as in panel A and studied at serial time points. (B) Sunitinib-treated recipients showed significantly increased proportions of donor-derived Lin− marrow progenitors compared with vehicle controls at all time points. (C) Significantly increased donor-derived CD3−B220−CD11b+ myeloid splenocytes on day 28 and 84 and significantly increased donor-derived CLPs (D), CMPs (E), CD150+ BM cells (F), and LSKFlt3−CD150+ BM cells (G) on day 28. *P < .05. **P < .005. ***P < .001. Radiation therapy composed Rag1−/− recipients conditioned with 1000 cGY before BMT as controls. (B-C) Day 14, n = 4 or 5 mice/group; day 28, n = 8 to 13 mice/group; day 84, n = 4 to 15 mice/group. Data represent pooled results from 2 independent experiments. Experiments were repeated 2 to 5 times with similar results. (D-F) n = 10 mice/group; only day 28 data are available for the cell subsets.
